# Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

> **NCT00676650** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 873 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Prednisone
- **DRUG:** sunitinib
- **DRUG:** Placebo
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00676650
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 873 (ACTUAL)
- **Why stopped:** Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or unexpected safety issues were identified.
- **Last updated:** 2013-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676650, "Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00676650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*